Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
ACS Medicinal Chemistry Letters
|
November 19, 2021
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors
Derun Li, Hongjun Zhang, Thomas W Lyons, et al.
ACS Medicinal Chemistry Letters
|
September 16, 2021
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology
Min Lu, Hongjun Zhang, Derun Li, et al.
ACS Medicinal Chemistry Letters
|
April 16, 2020
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy
Matthew J Mitcheltree, Derun Li, Abdelghani Achab, et al.
Oncoimmunology
|
April 2, 2021
Combination of EP<sub>4</sub> antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells
Yun Wang, Long Cui, Peter Georgiev, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 1, 2007
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors
Christopher L Hamblett, Joey L Methot, Dawn M Mampreian, et al.
Journal of Medicinal Chemistry
|
June 26, 2024
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> Inhibitor
Xiaoshen Ma, David L Sloman, Ruchia Duggal, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 10, 2008
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)
Joey L Methot, Prasun K Chakravarty, Melissa Chenard, et al.
ACS Medicinal Chemistry Letters
|
April 22, 2022
Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors
Chunhui Huang, Christian Fischer, Michelle R Machacek, et al.
Journal of Medicinal Chemistry
|
April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
Xiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Journal of Medicinal Chemistry
|
March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing
Derun Li, David L Sloman, Abdelghani Achab, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
ACS Medicinal Chemistry Letters
|
November 19, 2021
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors
Derun Li, Hongjun Zhang, Thomas W Lyons, et al.
ACS Medicinal Chemistry Letters
|
September 16, 2021
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology
Min Lu, Hongjun Zhang, Derun Li, et al.
ACS Medicinal Chemistry Letters
|
April 16, 2020
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy
Matthew J Mitcheltree, Derun Li, Abdelghani Achab, et al.
Oncoimmunology
|
April 2, 2021
Combination of EP<sub>4</sub> antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells
Yun Wang, Long Cui, Peter Georgiev, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 1, 2007
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors
Christopher L Hamblett, Joey L Methot, Dawn M Mampreian, et al.
Journal of Medicinal Chemistry
|
June 26, 2024
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> Inhibitor
Xiaoshen Ma, David L Sloman, Ruchia Duggal, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 10, 2008
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)
Joey L Methot, Prasun K Chakravarty, Melissa Chenard, et al.
ACS Medicinal Chemistry Letters
|
April 22, 2022
Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors
Chunhui Huang, Christian Fischer, Michelle R Machacek, et al.
Journal of Medicinal Chemistry
|
April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
Xiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Journal of Medicinal Chemistry
|
March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing
Derun Li, David L Sloman, Abdelghani Achab, et al.
Page
of 5